PIK3CA

Amid concerns about buparlisib's toxicity profile, a study suggests there might be a benefit for a subpopulation of patients with a more targeted PI3K inhibitor.

Early data presented at SABCS suggests that ER/PR-positive breast cancer patients could respond particularly well to Genentech's PI3 kinase inhibitor.

Originally published Dec. 12. SAN ANTONIO, TEX. – Fifteen years after it came on the market, Herceptin is still the poster child for personalized medicine, and when combined with chemotherapy it's still the standard of care for HER2-positive breast cancer.

By Ben Butkus
German molecular diagnostic services company Inostics is currently beta-testing its first assay kits featuring its BEAMing digital PCR technology, company officials said recently.

The patent application was filed by Montefiore Medical Center's Sanjay Goel and John Mariadason, who discovered the association between mutations in the PIK3CA and PTEN genes and a lack of response to EGFR inhibitors.

Product Watch

Premium

Life Tech's Ion OneTouch system; Transgenomic's Surveyor Scan BRAF and PIK3CA mutation-detection kits.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.